Compare FSUN & RAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | FSUN | RAPP |
|---|---|---|
| Founded | 1892 | 2022 |
| Country | United States | United States |
| Employees | 1186 | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.8B |
| IPO Year | N/A | 2024 |
| Metric | FSUN | RAPP |
|---|---|---|
| Price | $35.21 | $41.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $45.00 | ★ $48.50 |
| AVG Volume (30 Days) | 332.6K | ★ 463.5K |
| Earning Date | 04-27-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 24.34 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $79.34 | N/A |
| Revenue Next Year | $14.67 | N/A |
| P/E Ratio | $11.30 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $29.95 | $13.43 |
| 52 Week High | $42.34 | $43.76 |
| Indicator | FSUN | RAPP |
|---|---|---|
| Relative Strength Index (RSI) | 39.44 | 60.37 |
| Support Level | $34.48 | $33.54 |
| Resistance Level | $37.48 | $43.76 |
| Average True Range (ATR) | 1.32 | 2.75 |
| MACD | -0.22 | 0.22 |
| Stochastic Oscillator | 16.63 | 68.94 |
Firstsun Capital Bancorp is the financial holding company. It provides a full range of deposit, lending, treasury management, wealth management, and online banking products and services. The company operates in two segments; Banking operations and mortgage operations, the majority of which are generated by the banking operations segment. The Banking segment originates loans and provides deposits and fee based services to consumer, business, and mortgage lending customers. Products offered include a full range of commercial and consumer banking and financial services. The Mortgage Operations segment originates, sells, services, and manages market risk from changes in interest rates on one-to-four family residential mortgage loans.
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.